Mc Callion Orla
General Counsel at ULTIMOVACS ASA
Profile
Mc Callion Orla is currently the Head of Regulatory Affairs & QA at Ultimovacs ASA since 2021.
Prior to this, he worked as the Director of Regulatory Affairs at OxThera AB from 2012 to 2021.
Dr. Orla holds a doctorate degree from Queen's University.
Mc Callion Orla active positions
Companies | Position | Start |
---|---|---|
ULTIMOVACS ASA | General Counsel | 2021-09-30 |
Former positions of Mc Callion Orla
Companies | Position | End |
---|---|---|
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | General Counsel | 2021-09-30 |
Training of Mc Callion Orla
Queen's University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
ULTIMOVACS ASA | Health Technology |
Private companies | 1 |
---|---|
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Health Technology |
- Stock Market
- Insiders
- Mc Callion Orla